var data={"title":"Dantrolene: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dantrolene: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5976?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dantrolene-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dantrolene: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dantrolene-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dantrolene: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708692\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene has a potential for hepatotoxicity; do not use in conditions other than those recommended. Symptomatic hepatitis (fatal and nonfatal) has been reported at various dose levels of the drug. The incidence reported in patients taking dosages of up to 400 mg/day is much lower than in those taking dosages of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in women, patients older than 35 years, and patients taking other medication(s). Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving dantrolene. However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications. Use dantrolene only in conjunction with appropriate monitoring of hepatic function, including frequent determination of AST or ALT. If no observable benefit is derived from dantrolene after a total of 45 days, discontinue therapy. Prescribe the lowest possible effective dose for the individual patient.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156723\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dantrium;</li>\n      <li>Revonto;</li>\n      <li>Ryanodex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156724\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dantrium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156761\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Skeletal Muscle Relaxant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156727\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic spasticity:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Dose should be titrated and individualized for maximum effect; use the lowest dose compatible with optimal response. Some patients may not respond until a higher daily dosage is achieved; each dose level should be maintained for 7 days to determine patient response. If no further benefit observed with the higher dose level, then decrease dosage to previous dose level. Because of the potential for hepatotoxicity, stop therapy if benefits are not evident within 45 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 25 mg once daily for 7 days; increase to 25 mg 3 times daily for 7 days, increase to 50 mg 3 times daily for 7 days, and then increase to 100 mg 3 times daily; some patients may require 100 mg 4 times daily; maximum dose: 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant hyperthermia (MH):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preoperative prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 4 to 8 mg/kg/day in 3 to 4 divided doses, begin 1 to 2 days prior to surgery with last dose ~3 to 4 hours before scheduled surgery</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 2.5 mg/kg ~1<sup>1</sup>/<sub>4</sub> hours prior to anesthesia and infused over at least 1 minute (Ryanodex) or 1 hour (Dantrium, Revonto) with additional doses as needed and individualized</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Crisis: IV: 2.5 mg/kg (MHAUS recommendation, available at www.mhaus.org); continuously repeat dose until symptoms subside or a cumulative dose of 10 mg/kg is reached (rarely, some patients may require up to 30 mg/kg for initial treatment). Note: Manufacturer's labeling suggests an initial minimum dose of 1 mg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>24-hour MH Hotline (for emergencies only):</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">United States: 1-800-644-9737</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Outside the US: 00-1-209-417-3722</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postcrisis follow-up:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">MHAUS protocol suggestion: 1 mg/kg every 4 to 6 hours (route not specified) <b>or</b> a continuous IV infusion of 0.25 mg/kg/hour for at least 24 hours; further doses may be indicated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Oral: 4 to 8 mg/kg/day in 4 divided doses for 1 to 3 days; IV dantrolene may be used to prevent or attenuate recurrence of MH signs when oral therapy is not practical; individualize dosage beginning with 1 mg/kg or more as the clinical situation dictates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroleptic malignant syndrome (off-label use):</b> IV: 1 to 2.5 mg/kg initially; if rapid resolution of hyperthermia and rigidity is observed, may follow with 1 mg/kg every 6 hours up to a maximum cumulative dose of 10 mg/kg/day, then switch to oral dosage (Bienvenu 2012; Pileggi 2016; Strawn 2007; Susman, 2001). <b>Note:</b> Based on an analysis of 271 case reports, the use of dantrolene in combination with other therapies (eg, bromocriptine) may be preferred over dantrolene alone due to lower mortality and longer complete time of remission (Reulbach 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156745\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dantrolene-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dantrolene: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic spasticity:</b> Children &ge;5 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Dose should be titrated and individualized for maximum effect; use the lowest dose compatible with optimal response. Some patients may not respond until a higher daily dosage is achieved; each dose level should be maintained for 7 days to determine patient response. If no further benefit observed with the higher dose level, then decrease dosage to previous dose level. Because of the potential for hepatotoxicity, stop therapy if benefits are not evident within 45 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 0.5 mg/kg/dose once daily for 7 days; increase to 0.5 mg/kg/dose 3 times daily for 7 days, increase to 1 mg/kg/dose 3 times daily for 7 days, and then increase to 2 mg/kg/dose 3 times daily; some patients may require 2 mg/kg/dose 4 times daily; maximum dose: 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant hyperthermia (MH):</b> Infants, Children, and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156728\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292521\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292522\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use of oral dantrolene in patients with active liver disease (eg, hepatitis and cirrhosis) is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156704\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium: 25 mg, 50 mg, 100 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium: 20 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revonto: 20 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ryanodex: 250 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156689\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156706\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Therapeutic or emergency dose can be administered with rapid continuous IV push. Follow-up doses should be administered over at least 1 minute (Ryanodex) or 1 hour (Dantrium, Revonto).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156705\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic spasticity:</b> Oral: Treatment of spasticity associated with upper motor neuron disorders (eg, spinal cord injury, stroke, cerebral palsy, or multiple sclerosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant hyperthermia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Management of malignant hyperthermia (MH); prevention of MH in susceptible individuals (preoperative/postoperative administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Prevention of MH preoperatively in susceptible individuals who require anesthesia and/or surgery; following a malignant hyperthermic crisis to prevent recurrence of signs of malignant hyperthermia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Dantrolene prophylaxis is not recommended for most MH-susceptible patients, provided nontriggering anesthetics are used and an adequate supply of dantrolene is available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725531\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Neuroleptic malignant syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156768\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium may be confused with danazol, Daraprim</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revonto may be confused with Revatio</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156696\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing (intravenous: 27%), atrioventricular block (intravenous: 3%), tachycardia (3%), cardiac failure, phlebitis, variable blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Drowsiness (17%; drowsiness may persist for 48 hours post dose), voice disorder (intravenous: 13%), feeling abnormal (intravenous: 10%), dizziness (3%), headache (3%), myasthenia (3%), chills, choking sensation, confusion, depression, fatigue, insomnia, malaise, nervousness, seizure, speech disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acneiform eruption (capsules), diaphoresis, eczematous rash, erythema (intravenous), hair disease (abnormal growth), pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Dysphagia (10%; use caution at meal time on day of administration as swallowing may be difficult), nausea (10%), vomiting (3%), abdominal cramps, anorexia, constipation, diarrhea, dysgeusia, gastric irritation, gastrointestinal hemorrhage, sialorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Crystalluria, difficulty in micturition, erectile dysfunction, hematuria, nocturia, urinary frequency, urinary incontinence, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, aplastic anemia, leukopenia, lymphocytic lymphoma, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (intravenous: 3%; pain, erythema, swelling), local tissue necrosis (with extravasation due to high product pH)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Limb pain (intravenous: 3%), back pain, myalgia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision (intravenous: 3%), diplopia, epiphora, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea (intravenous), pleural effusion (with pericarditis), pulmonary edema (rare), respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Decrease in forced vital capacity (intravenous), dyspnea (intravenous), hepatic disease, hepatotoxicity (oral), increased liver enzymes (oral), respiratory muscle failure (intravenous)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156710\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no contraindications listed within the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Active hepatic disease (eg, cirrhosis, hepatitis); when spasticity is used to maintain upright posture/balance in locomotion or to obtain/maintain increased function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156693\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Oral: Has potential for hepatotoxicity; symptomatic hepatitis (fatal and nonfatal) has been reported.</b> <b>Higher doses (ie, &ge;800 mg/day), even sporadic short courses, may increase the risk of severe hepatic injury although hepatic injury may occur at doses &lt;400 mg/day. Overt hepatitis has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in patients &gt;35 years, and in those taking concurrent medications. A higher incidence of fatal hepatic events have been reported in the elderly, although concurrent disease states and concurrent use of potentially hepatotoxic drugs may have contributed. </b>Idiosyncratic and hypersensitivity reactions (sometimes fatal) of the liver have also occurred. Monitor hepatic function at baseline and as clinically indicated during treatment. Discontinue therapy if symptoms compatible with hepatitis, accompanied with abnormal liver function tests or jaundice occur or benefits are not observed within 45 days when utilized for chronic spasticity. Hepatic function usually reverts to normal upon discontinuation; if reinstitution of therapy is necessary, patients should be hospitalized and the drug initiated in very small and gradual dose increases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Muscle weakness: Loss of grip strength, weakness in the legs, dyspnea, respiratory muscle weakness, dysphagia, and decreased inspiratory capacity has occurred with IV dantrolene. Patients should not ambulate without assistance until they have normal strength and balance. Monitor patients for the adequacy of ventilation and for difficulty swallowing/choking.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Oral therapy may cause a photosensitivity reaction; use with caution during exposure to sunlight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pleural effusion: Pleural effusion with associated eosinophilia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use oral therapy with caution in patients with severely impaired cardiac function due to myocardial disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic disease: Use oral therapy with caution in patients with history of hepatic disease or dysfunction; use is contraindicated in patients with active hepatic disease (eg, cirrhosis, hepatitis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use oral therapy with caution in patients with impaired pulmonary function (particularly in obstructive pulmonary disease).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Alkaline solution; may cause tissue necrosis if extravasated (vesicant); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mannitol: Injection may contain mannitol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: IV dantrolene is not the only therapeutic approach for management of malignant hyperthermia. Supportive measures, including discontinuing trigger agents (eg, anesthetic agents), administering oxygen, utilizing cooling methods, and monitoring blood gases, urinary output, urine color, and electrolytes, must also be utilized and individualized. Administer diuretics to prevent late kidney injury due to myoglobinuria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156754\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156698\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9322&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Dantrolene may enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine).  Management: This interaction has only been described with intravenous dantrolene administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the hepatotoxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacidipine: May enhance the adverse/toxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: Dantrolene may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156700\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10460044\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Dantrolene crosses the human placenta. Cord blood concentrations are similar to those in the maternal plasma at term. and  dantrolene can be detected in the newborn serum at delivery. Adverse events were not observed in the newborn following maternal doses of 100 mg/day administered orally prior to delivery (Shime, 1988). Uterine atony has been reported following dantrolene injection after delivery; however, this may be due in part to the mannitol contained in the IV preparation (Shin, 1995; Weingarten, 1987). Prophylactic use of dantrolene is not routinely recommended in pregnant women susceptible to MH prior to obstetric surgery, if use is needed, close monitoring of the mother and newborn is recommended (Krause 2004; Norman 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10460045\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low amounts of dantrolene are present in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends that a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. In a case report, the half-life of dantrolene in breast milk was calculated to be 9 hours; the highest milk concentration was 1.2 mcg/mL following a maternal IV dose; however, the maternal serum concentrations were not reported (Fricker 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156702\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Motor performance should be monitored for therapeutic outcomes; nausea, vomiting, and liver function tests (baseline and at appropriate intervals thereafter) should be monitored for potential hepatotoxicity; intravenous administration requires cardiac, blood pressure, and respiratory monitoring.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Malignant hyperthermia: During and post-acute phase: Per MHAUS protocol, patient should be observed in an ICU for at least 24 hours since recrudescence may occur; monitor for arrhythmias; monitor vital signs (including core temperature), electrolytes, ABG, CK, end tidal CO<sub>2</sub> (EtCO<sub>2</sub>)/capnography, urine output, urine myoglobin </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156692\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts directly on skeletal muscle by interfering with release of calcium ion from the sarcoplasmic reticulum; prevents or reduces the increase in myoplasmic calcium ion concentration that activates the acute catabolic processes associated with malignant hyperthermia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156709\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 70% (Allen 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 36.4 &plusmn; 11.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; major metabolites are 5-hydroxy dantrolene and an acetylamino metabolite of dantrolene.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (at birth): ~20 hours (Shime 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 7 years: 10 hours (range: 8.1 to 14.8 hours) (Lerman 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 4 to 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IV: 1 minute post-dose (dantrolene); 24 hours post-dose (5-hydroxy dantrolene)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (45% to 50%); urine (25% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156712\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dantrium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $128.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $200.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dantrolene Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $96.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $155.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $195.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dantrium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $106.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Revonto Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Ryanodex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $3,008.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038594\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anorex (KR);</li>\n      <li>Dantamacrin (BG, CH, DE);</li>\n      <li>Dantrium (AU, BB, BE, CY, DK, FR, GB, GR, IE, IL, IT, JP, LU, MT, NL, NZ, PT, QA, SI, TR, VN, ZA);</li>\n      <li>Dantrolen (AR, AT, BG, BR, CZ, RU);</li>\n      <li>Degison (TW);</li>\n      <li>Relaxo (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allen GC, Cattran CB, Peterson RG, et al, &quot;Plasma Levels of Dantrolene Following Oral Administration in Malignant Hyperthermia-Susceptible Patients,&quot; Anesthesiology, 1988, 69(6):900-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. <i>Crit Care Med.</i> 2012;40(9):2662-2670.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/22732295/pubmed\" target=\"_blank\" id=\"22732295\">22732295</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dantrium capsules (dantrolene) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dantrium Intravenous (dantrolene) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricker RM, Hoerauf KH, Drewe J, et al, &quot;Secretion of Dantrolene Into Breast Milk After Acute Therapy of a Suspected Malignant Hyperthermia Crisis During Cesarean Section,&quot; <i>Anesthesiology</i>, 1998, 89(4):1023-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/9778021/pubmed\" target=\"_blank\" id=\"9778021\">9778021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guerrero RM and Shifrar KA, &ldquo;Diagnosis and Treatment of Neuroleptic Malignant Syndrome,&rdquo; <i>Clin Pharm</i>, 1988, 7(9):697-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/3240662/pubmed\" target=\"_blank\" id=\"3240662\">3240662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krause T, Gerbershagen MU, Fiege M, et al, &quot;Dantrolene -- A Review of its Pharmacology, Therapeutic Use and New Developments. <i>Anaesthesia</i>, 2004, 59(4):364-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/15023108/pubmed\" target=\"_blank\" id=\"15023108\">15023108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lerman J, McLeod ME, and Strong HA, &quot;Pharmacokinetics of Intravenous Dantrolene in Children,&quot; Anesthesiology, 1989, 70(4):625-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malignant Hyperthermia Association of the United States (MHAUS), 2011. Accessed May 15, 2012 at www.mhaus.org.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    May DC, Morris SW, Stewart RM, et al, &ldquo;Neuroleptic Malignant Syndrome: Response to Dantrolene Sodium,&rdquo; <i>Ann Intern Med</i>, 1983, 98(2):183-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/6824251/pubmed\" target=\"_blank\" id=\"6824251\">6824251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norman PF and Eichhorn JH, &quot;Management of Anesthetic Complications and Emergencies in the Obstetric Patient,&quot; <i>Obstet Gynecol Clin North Am</i>, 1995, 22(1):1-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/7784032/pubmed\" target=\"_blank\" id=\"7784032\">7784032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome Review: Focus on Treatment and Rechallenge [published online July 15, 2016]. <i>Ann Pharmacother</i>. 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/27423483/pubmed\" target=\"_blank\" id=\"27423483\">27423483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reulbach U, D&uuml;tsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. <i>Crit Care</i>. 2007;11(1):R4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/17222339/pubmed\" target=\"_blank\" id=\"17222339\">17222339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revonto (dantrolene) [prescribing information]. Louisville, KY: US WorldMeds LLC; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg MR and Green M, &ldquo;Neuroleptic Malignant Syndrome. Review of Response to Therapy,&rdquo; <i>Arch Intern Med</i>, 1989, 149(9):1927-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/2673115/pubmed\" target=\"_blank\" id=\"2673115\">2673115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin AS and Zablocki AD, &ldquo;Hyperkalemia, Verapamil, and Dantrolene,&rdquo; <i>Anesthesiology</i>, 1987, 66(2):248-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryanodex (dantrolene) [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shime J, Gare D, Andrews J, et al, &quot;Dantrolene in Pregnancy: Lack of Adverse Effects on the Fetus and Newborn Infant,&quot; <i>Am J Obstet Gynecol</i>, 1988, 159(4):831-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/3177531/pubmed\" target=\"_blank\" id=\"3177531\">3177531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shin YK, Kim YD, Collea JV, et al, &quot;Effect of Dantrolene Sodium on Contractility of Isolated Human Uterine Muscle,&quot; <i>Int J Obstet Anesth</i>, 1995, 4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/15637010/pubmed\" target=\"_blank\" id=\"15637010\">15637010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strawn JR, Keck PE, Caroff SN, &quot;Neuroleptic Malignant Syndrome,&quot; <i>Am J Psychiatry</i>, 2007, 164:870-876.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/17541044/pubmed\" target=\"_blank\" id=\"17541044\">17541044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Susman VL, &quot;Clinical Management of Neuroleptic Malignant Syndrome,&quot; <i>Psychiatric Quarterly</i>, 2001, 72(4):325-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/11525080/pubmed\" target=\"_blank\" id=\"11525080\">11525080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tayeb OS, &ldquo;A Serious Interaction of Dantrolene and Theophylline,&rdquo; <i>Vet Hum Toxicol</i>, 1990, 32(5):442-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/2122577/pubmed\" target=\"_blank\" id=\"2122577\">2122577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward A, Chaffman MO, and Sorkin EM, &ldquo;Dantrolene: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Malignant Hyperthermia, the Neuroleptic Malignant Syndrome and an Update of Its Use in Muscle Spasticity,&rdquo; <i>Drugs</i>, 1986, 32(2):130-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/3527659/pubmed\" target=\"_blank\" id=\"3527659\">3527659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weingarten AE, Korsh JI, Neuman GG, et al, &quot;Postpartum Uterine Atony After Intravenous Dantrolene,&quot; <i>Anesth Analg</i>, 1987, 66(3):269-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-drug-information/abstract-text/3826671/pubmed\" target=\"_blank\" id=\"3826671\">3826671</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9322 Version 180.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708692\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156723\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156724\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156761\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156727\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F156745\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156728\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14292521\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14292522\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156704\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F156689\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F156706\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156705\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725531\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156768\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156696\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156710\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156693\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F156754\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156698\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156700\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10460044\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10460045\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156702\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156692\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F156709\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F156712\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038594\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9322|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dantrolene-patient-drug-information\" class=\"drug drug_patient\">Dantrolene: Patient drug information</a></li><li><a href=\"topic.htm?path=dantrolene-pediatric-drug-information\" class=\"drug drug_pediatric\">Dantrolene: Pediatric drug information</a></li></ul></div></div>","javascript":null}